Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Levofloxacin Oral Solution issued by the National Medical Products Administration. Levofloxacin is a third-generation quinolone antibiotic, with its primary mechanism of action being the inhibition of bacterial DNA gyrase activity, thereby obstructing bacterial DNA replication. It is characterized by a broad antibacterial spectrum and strong antimicrobial effects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments